Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma

Journal of Clinical Oncology

Volumn 28, Issue 31, 2010, Pages 4722-4729

  Sampson, John H ^a   Heimberger, Amy B ^a   Archer, Gary E ^a   Aldape, Kenneth D ^a   Friedman, Allan H ^a   Friedman, Henry S ^a   Gilbert, Mark R ^a   Herndon II, James E ^a   McLendon, Roger E ^a   Mitchell, Duane A ^a   Reardon, David A ^a   Sawaya, Raymond ^a   Schmittling, Robert J ^a   Shi, Weiming ^a   Vredenburgh, James J ^a   Bigner, Darell D ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 3; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PEPTIDE VACCINE; TEMOZOLOMIDE; ALKYLATING AGENT; CANCER VACCINE; DACARBAZINE; DNA METHYLTRANSFERASE; DRUG DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR VIII; MGMT PROTEIN, HUMAN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ANTIBODY SPECIFICITY; ARTICLE; AUTOIMMUNITY; CANCER DIAGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; MALE; METHYLATION; MINIMAL RESIDUAL DISEASE; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; TUMOR CELL; TUMOR GENE; TUMOR GROWTH; VACCINATION; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BRAIN TUMOR; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DNA METHYLATION; DRUG ADMINISTRATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; INTRADERMAL DRUG ADMINISTRATION; MIDDLE AGED; MORTALITY; MUTATION; PREDICTION AND FORECASTING; PROSPECTIVE STUDY; SAMPLE SIZE; TIME; UNITED STATES;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CANCER VACCINES; CHEMOTHERAPY, ADJUVANT; DACARBAZINE; DISEASE-FREE SURVIVAL; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DRUG ADMINISTRATION SCHEDULE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRADERMAL; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MUTATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RADIOTHERAPY, ADJUVANT; RECEPTOR, EPIDERMAL GROWTH FACTOR; SAMPLE SIZE; TIME FACTORS; TUMOR SUPPRESSOR PROTEINS; UNITED STATES;

EID: 78149254368     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.28.6963     Document Type: Article

References (31)

1. Imperato JP, Paleologos NA, Vick NA: Effects of treatment on long-term survivors with malignant astrocytomas. Ann Neurol 28:818-822, 1990
2. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996, 2005 (Pubitemid 40349501)
3. Wong AJ, Ruppert JM, Bigner SH, et al: Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci U S A 89:2965-2969, 1992
4. Heimberger AB, Hlatky R, Suki D, et al: Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res 11:1462-1466, 2005 (Pubitemid 40315227)
5. Ge H, Gong X, Tang CK: Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis. Int J Cancer 98:357-361, 2002 (Pubitemid 34188678)
6. Sok JC, Coppelli FM, Thomas SM, et al: Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 12: 5064-5073, 2006 (Pubitemid 44453332)
7. Wikstrand CJ, Hale LP, Batra SK, et al: Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 55:3140-3148, 1995
8. Purev E, Cai D, Miller E, et al: Immune responses of breast cancer patients to mutated epidermal growth factor receptor (EGF-RvIII, Delta EGF-R, and de2-7 EGF-R). J Immunol 173:6472-6480, 2004 (Pubitemid 39487809)
9. Humphrey PA, Wong AJ, Vogelstein B, et al: Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Natl Acad Sci U S A 87:4207-4211, 1990
10. Chu CT, Everiss KD, Wikstrand CJ, et al: Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII). Biochem J 324:855-861, 1997 (Pubitemid 27285544)
11. Batra SK, Castelino-Prabhu S, Wikstrand CJ, et al: Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ 6:1251-1259, 1995
12. Lal A, Glazer CA, Martinson HM, et al: Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res 62:3335-3339, 2002 (Pubitemid 34651373)
13. Boockvar JA, Kapitonov D, Kapoor G, et al: Constitutive EGFR signaling confers a motile phenotype to neural stem cells. Mol Cell Neurosci 24: 1116-1130, 2003 (Pubitemid 38091521)
14. Nagane M, Coufal F, Lin H, et al: A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res 56:5079-5086, 1996 (Pubitemid 26374452)
15. Lammering G, Valerie K, Lin PS, et al: Radiation-induced activation of a common variant of EGFR confers enhanced radioresistance. Radiother Oncol 72:267-273, 2004 (Pubitemid 39265379)
16. Montgomery RB, Guzman J, O'Rourke DM, et al: Expression of oncogenic epidermal growth factor receptor family kinases induces paclitaxel resistance and alters beta-tubulin isotype expression. J Biol Chem 275:17358-17363, 2000 (Pubitemid 30430771)
17. Heimberger AB, Archer GE, Crotty LE, et al: Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma. Neurosurgery 50:158-166, 2002
18. Heimberger AB, Crotty LE, Archer GE, et al: Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res 9:4247-4254, 2003 (Pubitemid 37204046)
19. Macdonald DR, Cascino TL, Schold SC Jr, et al: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280, 1990 (Pubitemid 20195640)
20. Schmittling RJ, Archer GE, Mitchell DA, et al: Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines. J Immunol Methods 339:74-81, 2008
21. Pelloski CE, Ballman KV, Furth AF, et al: Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol 25:2288-2294, 2007 (Pubitemid 46954657)
22. Hegi ME, Diserens AC, Gorlia T, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003, 2005 (Pubitemid 40349502)
23. Westphal M, Hilt DC, Bortey E, et al: A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 5:79-88, 2003 (Pubitemid 36422560)
24. Wheeler CJ, Black KL, Liu G, et al: Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res 68: 5955-5964, 2008
25. De Vleeschouwer S, Fieuws S, Rutkowski S, et al: Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res 14:3098-3104, 2008
26. Yu JS, Liu G, Ying H, et al: Vaccination with tumor lysate-pulsed dendritic cells elicits antigenspecific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 64:4973-4979, 2004 (Pubitemid 38924545)
27. Yu JS, Wheeler CJ, Zeltzer PM, et al: Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 61:842-847, 2001 (Pubitemid 32175145)
28. Liau LM, Prins RM, Kiertscher SM, et al: Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 11:5515-5525, 2005 (Pubitemid 41060828)
29. Murat A, Migliavacca E, Gorlia T, et al: Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol 26:3015-3024, 2008
30. Kikuchi T, Akasaki Y, Abe T, et al: Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J Immunother 27:452-459, 2004 (Pubitemid 39447353)
31. Rutkowski S, De Vleeschouwer S, Kaempgen E, et al: Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study. Br J Cancer 91:1656-1662, 2004 (Pubitemid 39546137)